HIV ENVELOPE SPECIFIC DARPIN-BASED MICROBICIDE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 将体外抑制HIV和SIV感染的DARPin57.2注射到9只感染Shiv-RT的恒河猴体内。早在注射后30分钟，直到注射后24小时，外周血中就检测到达平结合的CD4阳性细胞。Darpin 57.2在体内和体外都结合了各种表达CD4的细胞类型，结合量与细胞表面的CD4量成正比。Darpin 57.2在注射后24小时内从血浆中清除。我们证明了CD4特异性DARPin可以在体内快速和选择性地结合其靶细胞，这为进一步研究DARPin技术可能的临床应用奠定了基础。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. CD4-specific DARPin 57.2, a potent inhibitor of HIV and SIV infection in vitro, was injected into 9 rhesus macaques infected with SHIV-RT. DARPin-bound CD4-positive cells were detected in the peripheral blood as early as 30 minutes after the injection and until the 24 hour mark. DARPin 57.2 bound the various CD4-expressing cell types both in vivo and in vitro with the amount of binding directly proportional to the amount of CD4 on the cell surface. DARPin 57.2 was cleared from the plasma within 24 hours after injection. We demonstrate that the CD4-specific DARPin can rapidly and selectively bind its target cells in vivo, warranting further studies on possible clinical use of the DARPin technology.